Non-pharmacological treatment methods for irritable bowel syndrome - literature overview
DOI:
https://doi.org/10.12775/JEHS.2025.80.56938Keywords
irritable bowel syndrome, non-pharmacological treatment, dietary, brain-gut axis, FODMAPAbstract
Introduction
Irritable bowel syndrome (IBS) is a prevalent condition involving the gut–brain interaction where individuals commonly experience recurring abdominal pain, changes in bowel movements, and frequently bloating.
Aim
The aim of this study was to review literature studies on IBS and non-pharmacological methods for treating this condition.
Method
Data for the article were retrieved by using Pub Med setting the time descriptor to 2019-2024.
Conclusions
Treating irritable bowel syndrome (IBS) continues to be challenging, as each patient needs a tailored approach. Once the correct IBS subtype is diagnosed, treatment should target the primary symptoms, such as bloating or diarrhea. Non-pharmacological treatment plays a initial, crucial and rapidly developing role in IBS therapy.
References
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10: 712-721.e4.
Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016; S0016-5085(16)00222-5
Fagoonee, S, Pellicano, R. Does the microbiota play a pivotal role in the pathogenesis of irritable bowel syndrome? J Clin Med. 2019; 8: 1808.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016; 150: 1262-1279.
Chojnacki C, Błońska A, Kaczka A, et al. Evaluation of serotonin and dopamine secretion and metabolism in patients with irritable bowel syndrome. Pol Arch Intern Med. 2018; 128: 711-713.
Mei L, Zhou J, Su Y, et al. Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2021; 21: 105.
Polster A, Öhman L, Tap J, et al. A novel stepwise integrative analysis pipeline reveals distinct microbiota-host interactions and link to symptoms in irritable bowel syndrome. Sci Rep. 2021; 11: 5521
Adriani A, Ribaldone DG, Astegiano M, et al. Irritable bowel syndrome: the clinical approach. Panminerva Med. 2018; 60: 213-222.
Tap J, Störsrud S, Le Nevé B, et al. Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020; 396: 1675-1688.
Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70: 1214-1240.
Irritable bowel syndrome in adults: diagnosis and management. London, United Kingdom: National Institute for Health and Care Excellence; 2017.
Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022; 71:1117-1126
Wu J, Masuy I, Biesiekierski JR, Fitzke HE, Parikh C, Schofield L, Shaikh H, Bhagwanani A, Aziz Q, Taylor SA, Tack J, Van Oudenhove L. Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;55:670-682.
Chey WD, Hashash JG, Manning L, Chang L. AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review. Gastroenterology. 2022;162:1737-1745.e5.
Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Nutrition. 2018;45:24-31.
Surdea-Blaga T, Cozma-Petrut A, Dumitraşcu DL. Dietary interventions and irritable bowel syndrome – what really works?. Curr Opin Gastroenterol. 2021;37(2):152–157
Adriani A, Saracco GM, Pellicano R. Irritable bowel syndrome and lactose intolerance: a challenging overlap. Minerva Gastroenterol. 2021; 67: 67-68.
Dumitrascu DL, Baban A, Bancila I, Barboi O, et al. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis. 2021;30(2):291–306. doi: 10.15403/jgld-3581.
El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11(8):1824. doi: 10.3390/nu11081824.
Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;376:2566–2578. doi: 10.1056/NEJMra1607547
Nagarajan N, Morden A, Bischof D, King EA, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27:1002–1010. doi: 10.1097/MEG.0000000000000425
Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367–1374. doi: 10.1038/ajg.2014.195.
McRorie JW. Evidence-Based Approach to Fiber Supplementsand Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today. 2015;50:82–89. doi: 10.1097/NT.0000000000000082
Moayyedi P, Andrews CN, MacQueen G, Korownyk C, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019 Apr;2(1):6–29. doi: 10.1093/jcag/gwy071
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care?Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi: 10.1136/bmj.b3154.
Muir J. An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2019;15:387–389.
Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7(1):87–92. doi: 10.1111/j.1365-2036.1993.tb00074.x.
McKenzie YA, Bowyer RK, Leach H, Gulia P, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016 Oct;29(5):549–75. doi: 10.1111/jhn.12385.
Hill C, Guarner F, Reid G, Gibson GR, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506–14. doi: 10.1038/nrgastro.2014.66.
Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016;22(7):2219–2241. doi: 10.3748/wjg.v22.i7.2219.
Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823–1836. doi: 10.1042/BCJ20160510.
Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther. 2018;35(3):289–310. doi: 10.1007/s12325-018-0673-5
McKenzie YA, Thompson J, Gulia P, Lomer MC, (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association) British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):576–592. doi: 10.1111/jhn.12386
Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Nov;48(10):1044–1060. doi: 10.1111/apt.15001.
Fukudo S, Okumura T, Inamori M, Okuyama Y, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193–217. doi: 10.1007/s00535-020-01746-z
Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014; 20: 6759-6773.
Chen GR, Xie XF, Peng C. Treatment of Irritable Bowel Syndrome by Chinese Medicine: A Review. Chin J Integr Med. 2023;29:377-384
Chen M, Qin D, Huang SL, et al. Chinese herbal medicine versus antispasmodics in the treatment of irritable bowel syndrome: a network meta-analysis. Neurogastroenterol Motil. 2021 Mar 4.
WHO Guideline. Physical Activity. Updated 5 October 2022.
NICE. Irritable Bowel Syndrome in Adults: Diagnosis and Management; NICE Clinical Guidelines, No. 61; National Institute for Health and Care Excellence (NICE): London, UK, 2017.
Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridium difficile infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 2017; 45: 899-908.
Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018; 3: 17-24.
Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018; 67: 2107-2115.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Wojciech Urban, Kornelia Karamus, Rafał Wojciech Rejmak, Jan Biłogras, Martyna Borowska-Łygan, Konrad Strużek, Jakub Tomaszewski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 71
Number of citations: 0
